Exane Derivatives’s QuantumScape Corp QS Stock Holding History

Exane Derivatives’s Portfolio QS Stock Details QS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25,500	Closed	-$566K	–	1077
2021 Q4	$566K	Buy	+25,500	New	+$699K	0.14%	159
2021 Q2	–	Sell	-19,200	Closed	-$859K	–	1078
2021 Q1	$859K	Buy	+19,200	New	+$1.01M	0.25%	91

Other funds holding QS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIG

Capricorn Investment Group Palo Alto, California $602M AUM 165.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Exane Derivatives's QS Position: Q1 2022 in Review

Exane Derivatives sold out of QuantumScape Corp (QS) in Q1 2022, closing a stake of 25,500 shares — an estimated $566K sold.

Exane Derivatives first reported a position in QS in Q1 2021 and held it in 2 quarters. The position peaked at $859K in Q1 2021. 336 funds tracked by Wall St. Rank hold QS as of Q1 2022.

Exane Derivatives reported no remaining QuantumScape Corp position as of Q1 2022 after selling out during the quarter.
Exane Derivatives sold 25,500 QuantumScape Corp shares in Q1 2022, an estimated $566K.
Exane Derivatives first reported a position in QuantumScape Corp in Q1 2021 and held it in 2 quarters.
Exane Derivatives's QuantumScape Corp position peaked at $859K in Q1 2021.
336 funds tracked by Wall St. Rank held QuantumScape Corp as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.